Bioactive peptides and peptidases: biological and immunobiological activities in i...
| Grant number: | 16/25112-4 |
| Support type: | Regular Research Grants |
| Duration: | August 01, 2017 - July 31, 2019 |
| Field of knowledge: | Biological Sciences - Biochemistry |
| Principal Investigator: | Wagner Alves de Souza Júdice |
| Grantee: | Wagner Alves de Souza Júdice |
| Home Institution: | Pró-Reitoria Acadêmica. Universidade de Mogi das Cruzes (UMC). Campus da Sede Mogi das Cruzes. Mogi das Cruzes , SP, Brazil |
| Assoc. researchers: | Adelino Vieira de Godoy Netto ; Edgar Julian Paredes-Gamero |
Abstract
Proteases are involved in many physiological processes attending to the metabolic and functional demand of the organisms to which they participate. However, in many situations these same proteases can trigger unwanted processes that establish pathologies in humans. Therefore, the modulation of its activities is a way of controlling its actions in pathogenic mechanisms such as tumor progression, metastasis, viral capsid processing, bacterial toxin processing, in facilitating the invasion of parasitic microorganisms and fungi. Among these proteases we have the cysteine proteases lysosomal cathepsins L and B. Cathepsins, in addition to their role in metastatic processes, are also responsible for an important role in the execution of the apoptotic program in several types of tumoral strains, since this enzyme needs to be transferred from the lysosome to the cytosol, where it degrades proteins involved in apoptosis. Cathepsins are involved in programmed cell death and senescence, and in the control of cell proliferation and differentiation. By their deleterious actions in the human organism, these proteases become interesting targets for the development of new drugs. In this context, our objective is to evaluate two families of molecules, one belonging to the alkyltriazoles and alkylphospholipids (21 molecules) and another belonging to the organometallic palladium complexes (8 molecules). In order to do so, we will carry out a screening of inhibitory activity, determination of inhibitory potential IC50, determination of inhibition mechanism and constant of dissociation of inhibitor Ki, determination of the microscopic constants belonging to Ki = k -3 / k3 by time course kinetics, molecular docking having the kinetic data as beacon parameters for modeling. We will evaluate the cytotoxicity of the compounds on leukemic cell lines using flow cytometry and determining the type of cell death. (AU)